TBC
VRTX icon

Tweedy, Browne Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Tweedy, Browne Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Sell
40,121
-266
-0.7% -$118K 1.51% 17
2026
Q1 		$18M Buy
40,387
+1,239
+3% +$578K 1.43% 17
2025
Q4 		$17.7M Buy
39,148
+83
+0.2% +$35.8K 1.43% 19
2025
Q3 		$15.3M Buy
39,065
+1,812
+5% +$757K 1.33% 18
2025
Q2 		$16.6M Sell
37,253
-1,063
-3% -$490K 1.54% 17
2025
Q1 		$18.6M Sell
38,316
-2,315
-6% -$1.08M 1.65% 16
2024
Q4 		$16.4M Sell
40,631
-12,969
-24% -$6.01M 1.1% 20
2024
Q3 		$24.9M Sell
53,600
-746
-1% -$358K 1.19% 18
2024
Q2 		$25.5M Sell
54,346
-12,353
-19% -$5.36M 1.17% 18
2024
Q1 		$27.9M Sell
66,699
-65
-0.1% -$27.5K 1.31% 16
2023
Q4 		$27.2M Sell
66,764
-8,240
-11% -$3.04M 1.33% 16
2023
Q3 		$26.1M Buy
+75,004
New +$26.2M 1.4% 14

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tweedy, Browne Co's VRTX Position: Q2 2026 in Review

Tweedy, Browne Co reduced its Vertex Pharmaceuticals (VRTX) stake by 0.66% in Q2 2026, selling an estimated $118K and leaving 40,121 shares worth $19.9M. The position accounts for 1.51% of the portfolio, ranked #17.

Tweedy, Browne Co first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $27.9M in Q1 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Tweedy, Browne Co held 40,121 shares of Vertex Pharmaceuticals worth $19.9M as of Q2 2026.
  • Tweedy, Browne Co sold 266 Vertex Pharmaceuticals shares in Q2 2026, an estimated $118K.
  • Vertex Pharmaceuticals made up 1.51% of Tweedy, Browne Co's portfolio in Q2 2026, its #17 holding.
  • Tweedy, Browne Co first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Tweedy, Browne Co's Vertex Pharmaceuticals position peaked at $27.9M in Q1 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tweedy, Browne Co's 13F filing for Q2 2026, filed 7 Aug 2026.